Subsequent Events	9 Months Ended
Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	(13) Subsequent Events In September 2024, the Company entered into a Distribution and License Agreement (the “SPC License Agreement”) with SPC Korea Limited (“SPC”), pursuant to which the Company granted to SPC a non-transferable, exclusive, royalty-bearing license to commercialize the Company’s TLANDO® product with respect to testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone, as indicated in a New Drug Application (“NDA”) No. 208088, treatment of Klinefelter syndrome, and pediatric indications relating to testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone (the “Field”), specific to the country of South Korea (the “SPC Territory”). SPC paid the Company a one-time non-refundable, non-creditable upfront fee in October 2024. The Company is eligible to receive additional payments including a non-refundable, non-creditable prepayment in consideration for TLANDO product inventory, marketing authorization and sales milestones, and the Company will supply TLANDO to SPC and receive a supply price. In addition, the Company will receive royalties on net sales in the SPC Territory. In October 2024, the Company entered into a distribution and supply agreement (the “Pharmalink License Agreement”) with Pharmalink, pursuant to which the Company granted to Pharmalink a non-transferable, exclusive, license to commercialize the Company’s TLANDO® product with respect to the Field, specific to the Gulf Cooperation Council (GCC), including Saudi Arabia, Kuwait, the United Arab Emirates (UAE), Qatar, Bahrain, and Oman (the “GCC Territory”). Pharmalink paid the Company a one-time non-refundable, non-creditable upfront fee. The Company is eligible to receive additional payments in regulatory authorization milestones related to the GCC under the Pharmalink License Agreement and the Company will supply TLANDO to Pharmalink at an agreed transfer price. On October 22, 2024, the Company adopted a Third Amended and Restated Stockholder Rights Agreement in order to extend the expiration date of the stockholder rights plan until October 22, 2027. Other than extending the expiration date of the Rights Agreement, no material changes have been made to the prior stockholder rights plan. See Footnote 9(c) Stockholder’s Equity, Rights Agreement.

Subsequent Events

9 Months Ended

Sep. 30, 2024

(13) Subsequent Events

In September 2024, the Company entered into a Distribution and License Agreement (the “SPC License Agreement”) with SPC Korea Limited (“SPC”), pursuant to which the Company granted to SPC a non-transferable, exclusive, royalty-bearing license to commercialize the Company’s TLANDO® product with respect to testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone, as indicated in a New Drug Application (“NDA”) No. 208088, treatment of Klinefelter syndrome, and pediatric indications relating to testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone (the “Field”), specific to the country of South Korea (the “SPC Territory”).

SPC paid the Company a one-time non-refundable, non-creditable upfront fee in October 2024. The Company is eligible to receive additional payments including a non-refundable, non-creditable prepayment in consideration for TLANDO product inventory, marketing authorization and sales milestones, and the Company will supply TLANDO to SPC and receive a supply price. In addition, the Company will receive royalties on net sales in the SPC Territory.

In October 2024, the Company entered into a distribution and supply agreement (the “Pharmalink License Agreement”) with Pharmalink, pursuant to which the Company granted to Pharmalink a non-transferable, exclusive, license to commercialize the Company’s TLANDO® product with respect to the Field, specific to the Gulf Cooperation Council (GCC), including Saudi Arabia, Kuwait, the United Arab Emirates (UAE), Qatar, Bahrain, and Oman (the “GCC Territory”).

Pharmalink paid the Company a one-time non-refundable, non-creditable upfront fee. The Company is eligible to receive additional payments in regulatory authorization milestones related to the GCC under the Pharmalink License Agreement and the Company will supply TLANDO to Pharmalink at an agreed transfer price.

On October 22, 2024, the Company adopted a Third Amended and Restated Stockholder Rights Agreement in order to extend the expiration date of the stockholder rights plan until October 22, 2027. Other than extending the expiration date of the Rights Agreement, no material changes have been made to the prior stockholder rights plan. See Footnote 9(c) Stockholder’s Equity, Rights Agreement.